Company Overview and News
HONG KONG: Swiss bank UBS Group AG. has asked its China wealth management staff to reconsider their travel plans to the country after authorities there asked one of its bankers to delay her departure from Beijing to meet with local officials, a person familiar with the matter said.
HONG KONG (Reuters) - Swiss bank UBS Group AG. (UBSG.S) has asked its China wealth management staff to reconsider their travel plans to the country after authorities there asked one of its bankers to delay her departure from Beijing to meet with local officials, a person familiar with the matter said.
Two large global wealth managers have imposed restrictions on staff travel to China after a UBS Group AG employee was detained, underlining the challenges of capturing business in a country where fortunes are growing the fastest on the planet.
PARIS (Oct 19): A former Geneva-based HSBC Holdings Plc banker was found guilty of money laundering, but cleared of related drug charges in a French trial of four brothers accused of operating a sophisticated ring to distribute drug money to wealthy clients.
SCGLF UBS SCGLY GLE ULSGF
(Oct 16): The owner of the Canary Wharf skyscraper that’s leased to Citigroup Inc is considering a sale of the building for more than 1.2 billion pounds (US$1.6 billion), as investors continue to line up for London’s trophy buildings, people with knowledge of the plan said.
BNPQY SVS GS GLSSP SCGLF UBS JBK C GSC TFG SCGLY BNPQF GSJ BNPZY CGBBW GLE GJS ULSGF
(Bloomberg) -- Oil advanced amid growing international outrage over the disappearance of a prominent Saudi Arabian critics that put relations between the U.S. and kingdom on a knife edge.
UBS OXY ULSGF
There's little satisfaction writing the CBB after a big down week in the markets. Motivation seems easier to come by after up weeks, perhaps my defiant streak kicking in. I find myself especially melancholy at the end of this week. There's a rude awakening coming - perhaps it's finally starting to unfold.
DGLD BATS 4162 CS FMCKI FMCKJ UGLD SCGLF UBS FMCCO FMCCP DSLV FMCCM VIIX FMCCN CSSLF VIIZ FMCCI FMCCJ SCGLY FMCCG FMCKO NYTAB FMCKP FMCKM FMCKN FMCKK FMCKL CSGKF NDAQ T FMCC 2007 ZIV USLV GLE TVIX FMCCS ULSGF FMCCT XIV
HONG KONG (Reuters) - UBS Group AG (UBSG.S) may have moved a step closer towards becoming the first foreign bank to hold majority ownership of its Chinese investment banking operations, after two of its joint venture partners said they had put their stakes up for sale.
NMR 8604 N33 UBS NRSCF ULSGF
Hong Kong retail investors who trade callable bull/bear contracts actually made a profit overall. Despite steady recent inflows into derivatives betting that the benchmark Hang Seng Index and Tencent Holdings Ltd would rebound, their holdings of bearish contracts were enough to weather the losses.
UBS 0700 ULSGF
A French court on Thursday threw out a request by Swiss bank UBS for the constitutional court to drop money laundering charges and limit proceedings to complicity in tax fraud, which carries lighter penalties.
PARIS: A French court on Thursday (Oct 11) threw out a request by Swiss bank UBS to drop money laundering charges and limit trial proceedings to complicity in tax fraud, which carries lighter penalties.
PARIS (Reuters) - A French court on Thursday threw out a request by Swiss bank UBS (UBSG.S) to drop money laundering charges and limit trial proceedings to complicity in tax fraud, which carries lighter penalties.
NEW YORK, Oct 11 — A US prosecutor yesterday urged jurors in Manhattan federal court to find three former London-based currency traders guilty of scheming to rig prices, kicking off the latest trial to emerge from a US probe into the multitrillion-dollar foreign exchange market.
BCS BNPQY HSB 83SF 83SK UBS HSBC HBCYF 47MC C BNPQF HCS 0005 BNPZY CGBBW HSEA HSEB ULSGF
Bullish market: Cable cars move past residential flats at Lantau island in Hong Kong. An almost 15-year bull run in prices prompted UBS Group AG to name Hong Kong as the city most at risk of a housing bubble. — Reuters
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET